SYD-101

SYD-101 is a proprietary, stabilized low-dose atropine sulfate ophthalmic solution developed to slow the progression of myopia (nearsightedness) in pediatric patients. It is formulated as a 0.01% (and potentially also 0.03%) preservative-containing multi-dose eye drop designed for once-daily use at bedtime in children aged 3 to 14 years[2][5][7]. Atropine is an antimuscarinic agent that acts by blocking muscarinic acetylcholine receptors in the eye, thereby reducing axial elongation and slowing myopic progression[5]. Unlike compounded formulations, SYD-101 offers improved stability and consistency, addressing previous concerns about variability and efficacy with non-standardized preparations[2]. The drug has completed pivotal Phase 3 trials (STAR study), meeting its primary endpoint of reducing annual myopia progression over three years[4][6]. If approved by regulatory agencies such as the FDA or EMA, it would be the first pharmaceutical therapy specifically indicated for slowing pediatric myopia progression.

Brand names

Ryjunea

Other names

atropine sulfate ophthalmic solution 0.01%low-dose atropineSYD-101 eye dropsSYD101 eye dropsSYD 101 eye drops